DDC-induced Primary Sclerosing Cholangitis (PSC) Model

Model Overview and Example Data

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by periductal fibrosis, bile duct proliferation, and inflammation, ultimately leading to cirrhosis and liver failure. The 3,5-diethoxycarbonyl-1, 4-dihydrocollidine (DDC) model is a chemically induced PSC-like mouse model that can mimic key features of human PSC. DDC primarily damages cholangiocytes (bile duct epithelial cells), activates the innate immune system, triggers inflammatory responses, and ultimately results in bile duct hyperplasia and fibrosis.

Study Outline

图片1.png

Model Validation Data

图片2.png

Figure 1. 0.1% DDC treatment causes loss of body weight. Data presented as Mean±SD.

图片3.png

Figure 2. DDC treatment increases liver enzymes and induces liver damage.

Alanine transaminase (ALT) and aspartate transaminase (AST) levels are elevated following DDC-treatment. Data are presented as Mean±SD. *, P＜0.05; **, P＜0.01;***, P＜0.001;****, P<0.0001 by one way ANOVA with Tukey’s post hoc test.

图片4.png

Figure 3. DDC treatment increases Bilirubin and alkaline phosphatase (ALP), causing liver damage. Data presented as Mean±SD. *, P＜0.05; ****, P<0.0001 by one way ANOVA with Tukey’s post hoc test.

Figure 4. DDC treatment increases bile duct and cholangiocarcinoma resistance gene expression.

Figure 5. DDC treatment increases bile duct and cholangiocarcinoma resistance gene expression. Data presented as Mean±SD. **, P＜0.01; ****, P<0.0001 by one way ANOVA with Turkey’s post hoc test.

Figure 6. DDC treatment increases the uptake of bile acid by the liver and cholangiocyte. Data presented as Mean±SD. **, P＜0.01; ****, P<0.0001 by one way ANOVA with Turkey’s post hoc test.

Standard of Care Drug Efficacy

Figure 7. Obeticholic acid (OCA) moderately reduces body weight loss in PSC-treated mice. Data presented as Mean±SD. ****, P<0.0001 by one way ANOVA with Tukey’s post hoc test.

Figure 8. OCA significantly decreased liver enzyme and bilirubin, improving liver function. Data presented as Mean±SD. **, P＜0.01; ****, P<0.0001 by one way ANOVA with Tukey’s post hoc test.

Figure 9. OCA-treatment significantly decreases deposition of bilirubin. Data presented as Mean±SD. *, P＜0.05.

Figure 10. OCA significantly decreased inflammatory gene expression. Data presented as Mean±SD. **, P＜0.01; ****, P<0.0001 by one way ANOVA with Tukey’s post hoc test.

TALK WITH OUR EXPERTS

*

STATE/PROVINCE

*

How did you hear about us?

Search Engine Social Media Email Colleague Referral Conference Webinar Other

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

I agree to receive other communications from GemPharmatech.

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

I agree to allow GemPharmatech to store and process my personal data.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.